Patients Rewriting the MASLD playbook Effective care now requires identifying metabolic risks early and addressing the broader factors driving liver damage.
Patients Exploring the role of pharmacy and self-care in the fight ag... Globally, the incidence of fatty liver disease is increasing at a concerning rate, yet, the solution could be simple.
News Boehringer’s survodutide shows monster MASH potential Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the res
News EMA advisors say CSL's Tavneos should be pulled from sale Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
